Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$13.77 USD
+0.25 (1.85%)
Updated May 31, 2024 04:00 PM ET
After-Market: $13.75 -0.02 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRML 13.77 +0.25(1.85%)
Will TRML be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRML
Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
Here's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price Strength
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'
Other News for TRML
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio announces first patient dosed in Phase 2 TRANQUILITY trial
Buy Rating Affirmed for Tourmaline Bio Amid Progress in TOUR006 Trials and Expansion Opportunities
Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)